{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:31:27Z","timestamp":1758774687194,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ygyno.2020.07.020","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T07:23:21Z","timestamp":1597476201000},"page":"112-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice"],"prefix":"10.1016","volume":"159","author":[{"given":"Cortney M.","family":"Eakin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Ewongwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Pendleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana M.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ygyno.2020.07.020_bb0005","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2020.07.020_bb0010","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.ygyno.2020.07.020_bb0015","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ygyno.2020.07.020_bb0020","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.07.020_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40661-017-0050-0","article-title":"Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?","volume":"4","author":"Herzog","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2020.07.020_bb0030","first-page":"153","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J. Clin."},{"year":"2019","author":"American Society of Clinical Oncology (ASCO)","series-title":"ASCO Position Statement on Addressing the Affordability of Cancer Drugs","key":"10.1016\/j.ygyno.2020.07.020_bb0035"},{"year":"2019","author":"Society of Gynecologic Oncology (SGO)","series-title":"Addressing the High Cost of Drugs for Oncology Patients: A National Priority","key":"10.1016\/j.ygyno.2020.07.020_bb0040"},{"issue":"9","key":"10.1016\/j.ygyno.2020.07.020_bb0045","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.020_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2019.04.003","article-title":"Financial toxicity in gynecologic oncology","volume":"154","author":"Bouberhan","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.020_bb0055","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2016.348","article-title":"Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer","volume":"115","author":"Ledermann","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.020_bb0060","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.07.020_bb0065","first-page":"1219","article-title":"Cost effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"Zhong","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.020_bb0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.020_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.6004\/jnccn.2016.0033","article-title":"Outcome assessments and cost avoidance of an oral chemotherapy management clinic","volume":"14","author":"Wong","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"9","key":"10.1016\/j.ygyno.2020.07.020_bb0080","first-page":"1075","article-title":"Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey","volume":"16","author":"Kav","year":"2008","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.020_bb0085","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1200\/JOP.2015.007260","article-title":"Improving the safety of oral chemotherapy at an academic medical center","volume":"12","author":"Shah","year":"2016","journal-title":"J. Oncol. Pract."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.020_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2017.10.007","article-title":"Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer","volume":"147","author":"Dockery","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.07.020_bb0095","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1634\/theoncologist.2015-0268","article-title":"Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer","volume":"21","author":"Moore","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.020_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2018.01.010","article-title":"Management of the toxicities of common targeted therapeutics for gynecologic cancers","volume":"148","author":"Gunderson","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.020_bb0105","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LarFargue","year":"2019","journal-title":"Lancet Oncol."},{"year":"2017","author":"AstraZeneca Pharmaceuticals LP","series-title":"Lynparza (Olaparib) Capsules [Prescribing Information]","key":"10.1016\/j.ygyno.2020.07.020_bb0110"},{"year":"2016","author":"Clovis Oncology Inc","series-title":"Rubraca (Rucaparib) Tablets [Prescribing Information]","key":"10.1016\/j.ygyno.2020.07.020_bb0115"},{"year":"2017","author":"Tesaro Inc","series-title":"Zejula (Niraparib) Capsules [Prescribing Information]","key":"10.1016\/j.ygyno.2020.07.020_bb0120"},{"key":"10.1016\/j.ygyno.2020.07.020_bb0125","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:46Z","timestamp":1758772366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820336556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0090825820336556"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}